Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
AIFU | -15.89% | $4.18B | +24.38% | 0.00% |
ALNT | -13.60% | $581.68M | +33.39% | 0.36% |
CMP | -12.86% | $806.61M | +74.91% | 0.00% |
MGPI | -12.13% | $648.36M | -58.42% | 1.55% |
IRWD | -11.49% | $113.08M | -87.74% | 0.00% |
MTW | -11.02% | $400.51M | +3.39% | 0.00% |
GRPN | -9.60% | $1.47B | +148.19% | 0.00% |
HTLD | -9.58% | $684.99M | -25.47% | 0.92% |
ILPT | -9.29% | $313.51M | +31.67% | 0.84% |
LITB | -8.98% | $22.07M | -76.50% | 0.00% |
HAIN | -8.98% | $148.92M | -76.33% | 0.00% |
KELYA | -8.72% | $406.59M | -45.54% | 2.56% |
USNA | -8.60% | $566.89M | -33.01% | 0.00% |
DHC | -8.60% | $890.22M | +31.32% | 1.07% |
OFLX | -8.55% | $326.75M | -40.02% | 4.16% |
JBI | -8.50% | $1.10B | -40.59% | 0.00% |
HELE | -8.25% | $596.05M | -73.84% | 0.00% |
RLX | -8.07% | $1.97B | +20.56% | 0.47% |
VSA | -8.02% | $8.84M | -14.05% | 0.00% |
BMBL | -7.90% | $542.28M | -47.92% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
ALNY | 50.51% | $40.72B | +102.99% | 0.00% |
IONS | 44.59% | $5.89B | -8.93% | 0.00% |
ROIV | 42.51% | $7.78B | +5.54% | 0.00% |
GMAB | 37.21% | $13.25B | -16.43% | 0.00% |
HALO | 36.23% | $6.55B | +5.73% | 0.00% |
LLY | 35.43% | $744.00B | -11.94% | 0.72% |
CLDX | 34.92% | $1.38B | -39.93% | 0.00% |
SNY | 32.91% | $116.02B | +0.85% | 4.57% |
NVS | 32.53% | $220.04B | +10.50% | 3.43% |
IMVT | 32.01% | $2.71B | -39.44% | 0.00% |
ZYME | 31.90% | $887.30M | +48.24% | 0.00% |
RNA | 31.87% | $3.53B | -23.51% | 0.00% |
AMGN | 31.76% | $155.74B | -5.35% | 3.18% |
XENE | 31.54% | $2.45B | -12.00% | 0.00% |
NVO | 31.53% | $249.13B | -47.44% | 2.25% |
IBN | 31.52% | $116.65B | +21.16% | 0.72% |
OCUL | 31.49% | $1.33B | +51.73% | 0.00% |
KRYS | 31.22% | $3.82B | -23.65% | 0.00% |
MORN | 31.19% | $12.79B | +5.66% | 0.57% |
FOLD | 31.05% | $1.76B | -41.35% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
EVH | -0.01% | $1.02B | -60.81% | 0.00% |
TNC | -0.01% | $1.40B | -23.33% | 1.54% |
FLXS | 0.02% | $188.04M | +7.09% | 1.82% |
ACMR | 0.02% | $1.61B | +4.57% | 0.00% |
AVD | 0.02% | $137.96M | -53.94% | 0.75% |
REAL | -0.02% | $576.78M | +58.88% | 0.00% |
GPI | 0.03% | $5.68B | +42.33% | 0.44% |
PBH | 0.03% | $4.13B | +28.76% | 0.00% |
KLTR | 0.05% | $311.85M | +63.71% | 0.00% |
DQ | -0.06% | $943.87M | -23.15% | 0.00% |
GORV | -0.06% | $25.88M | -92.85% | 0.00% |
APOG | -0.13% | $810.72M | -39.21% | 2.68% |
CARM | -0.15% | $20.99M | -51.23% | 0.00% |
CWH | -0.15% | $1.12B | -3.08% | 2.77% |
LESL | -0.15% | $87.11M | -88.76% | 0.00% |
DINO | -0.16% | $7.81B | -20.50% | 4.81% |
HSII | 0.18% | $886.28M | +29.57% | 1.40% |
EZPW | -0.20% | $729.48M | +28.49% | 0.00% |
ATRC | -0.21% | $1.56B | +49.10% | 0.00% |
LOVE | -0.21% | $262.03M | -22.60% | 0.00% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
BBH | 50.76% | $336.53M | 0.35% |
FBT | 50.35% | $997.89M | 0.54% |
IBB | 48.49% | $5.44B | 0.45% |
XBI | 46.34% | $4.66B | 0.35% |
PPH | 45.44% | $563.37M | 0.36% |
IXJ | 44.94% | $3.71B | 0.41% |
PBE | 43.41% | $222.71M | 0.58% |
IHE | 42.79% | $561.01M | 0.39% |
VHT | 41.85% | $15.27B | 0.09% |
FHLC | 41.64% | $2.42B | 0.084% |
PTH | 41.56% | $101.31M | 0.6% |
IYH | 40.98% | $2.76B | 0.39% |
XLV | 40.14% | $33.98B | 0.09% |
GNOM | 39.99% | $43.17M | 0.5% |
XPH | 39.39% | $148.95M | 0.35% |
PINK | 37.77% | $131.33M | 0.5% |
IGRO | 37.12% | $1.17B | 0.15% |
IMOM | 37.03% | $100.74M | 0.39% |
VIGI | 36.41% | $8.20B | 0.1% |
ACWV | 35.24% | $3.28B | 0.2% |
Yahoo
VYVGART® SC, first-and-only IgG Fc-antibody fragment which specifically targets the neonatal Fc receptor (FcRn), now approved for use in Europe for CIDPApproval based on ADHERE clinical trial, the largest study of CIDP patients to dateFirst novel mechanism of action for CIDP treatment in more than 30 years June 20, 2025, 7:00 PM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoim
Yahoo
Amidst renewed uncertainty about U.S. trade policy and escalating geopolitical tensions in the Middle East, European markets have experienced a downturn, with the pan-European STOXX Europe 600 Index ending 1.57% lower and major stock indexes such as Germany’s DAX and Italy’s FTSE MIB also declining significantly. In this challenging environment, identifying high-growth tech stocks requires a focus on companies with robust innovation capabilities and resilience to macroeconomic pressures,...
Yahoo
Amidst a backdrop of renewed uncertainty about U.S. trade policy and escalating geopolitical tensions in the Middle East, European markets have seen declines, with the pan-European STOXX Europe 600 Index ending 1.57% lower and major stock indexes such as Germany’s DAX and Italy’s FTSE MIB experiencing notable drops. In this environment, identifying high-growth tech stocks requires a focus on companies demonstrating resilience through innovation and adaptability to shifting economic...
SeekingAlpha
Baker Brothersâ Q1 2025 portfolio reveals biotech investment trends. See more on their top holdings, stake changes, and high-conviction strategies.
SeekingAlpha
Halozyme navigates CMS pricing risks impacting 2028+ revenues, yet strong royalties, FY25 guidance, and margins support stable near-term earnings.
Yahoo
ALKIVIA data demonstrate significant improvement in muscle strength and physical function in myositis patients treated with efgartigimodRHO data show efgartigimod achieved sustained reduction in autoantibodies and improved functional outcomes in patients with Sjogren’s disease; program granted U.S. FDA Fast Track designationargenx committed to new therapeutic areas in rheumatology with ongoing Phase 3 studies in myositis (ALKIVIA) and Sjogren’s disease (UNITY) June 11, 2025, 12:01 AM CET Amsterd
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
TAIL | -25.98% | $101.78M | 0.59% |
VIXY | -25.74% | $185.08M | 0.85% |
TPMN | -18.33% | $30.91M | 0.65% |
TBLL | -13.81% | $2.22B | 0.08% |
GSST | -12.12% | $900.18M | 0.16% |
ULST | -10.37% | $668.01M | 0.2% |
BTAL | -9.61% | $291.48M | 1.43% |
IVOL | -8.86% | $349.05M | 1.02% |
BILZ | -8.80% | $840.74M | 0.14% |
XHLF | -8.70% | $1.72B | 0.03% |
USDU | -8.60% | $164.82M | 0.5% |
UUP | -8.23% | $197.14M | 0.77% |
BIL | -8.21% | $43.95B | 0.1356% |
TFLO | -7.78% | $6.92B | 0.15% |
TUR | -7.78% | $141.84M | 0.59% |
IBTG | -7.73% | $1.96B | 0.07% |
SPTS | -7.71% | $5.74B | 0.03% |
GBIL | -7.17% | $6.38B | 0.12% |
XBIL | -7.07% | $795.25M | 0.15% |
IBDQ | -7.07% | $3.04B | 0.1% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
VGIT | 0.04% | $31.64B | 0.04% |
ETHA | -0.06% | $4.22B | 0.25% |
ETHW | 0.06% | $261.91M | 0% |
ITM | -0.07% | $1.86B | 0.18% |
AGGH | -0.09% | $317.83M | 0.29% |
IEI | -0.12% | $15.31B | 0.15% |
AGZD | 0.13% | $111.91M | 0.23% |
ETH | -0.13% | $1.33B | 0% |
IBD | 0.22% | $383.50M | 0.43% |
QETH | -0.22% | $23.04M | 0.25% |
WEAT | 0.22% | $122.67M | 0.28% |
IBMS | 0.30% | $85.43M | 0.18% |
JMST | -0.32% | $4.00B | 0.18% |
FETH | -0.34% | $1.16B | 0.25% |
EZET | -0.35% | $35.50M | 0% |
NYF | 0.36% | $887.92M | 0.25% |
BSV | 0.36% | $38.05B | 0.03% |
CETH | -0.41% | $22.60M | 0% |
AGZ | -0.42% | $608.84M | 0.2% |
IBMR | -0.43% | $254.44M | 0.18% |
Current Value
$542.491 Year Return
Current Value
$542.491 Year Return